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Advances in Mycobacterium siderophore-based drug discovery 91. Introduction
Tuberculosis (TB) caused by Mycobacterium tuberculosis
(MTB) remains a prevalent and fatal infectious disease. One-
third of the world’s population is infected with MTB of which
5–10% is active TB. In 2009, there are 1.7 million people
estimated who died from TB. The emergence of multidrug-
resistant (MDR-TB) and extensively drug-resistant (XDR-TB)
strains of MTB has confounded attempts to control the
disease. There were almost 30,000 cases of MDR-TB in 2008
and at least 57 cases of XDR-TB by November 2009. Even in
a developed country like USA, the incidence of XDR-TB
increased from 3% to 11%, from 2000 to 2004, and the
incidence reaches 2.9% in 20091,2. For this reason, new
antituberculosis drugs, particularly those effective against
MDR-TB and XDR-TB, are urgently needed.
Iron is an essential cofactor for many enzymes3 and it is
logical that a successful pathogen like MTB would evolve an
elaborate system to maintain iron homeostasis. The host has
only a limited supply of iron, because the majority of iron is
protected by proteins or presented in the indissoluble form3,4.
During infection, the host will trigger a series of protective
mechanisms to safeguard its iron homeostasis5,6. Faced with
such defense mechanisms, the ability of a pathogen, particu-
larly an intracellular one, to obtain iron determines its fate
during the infection7–9. A variety of strategies have evolved by
which bacteria obtain iron, including siderophore biosynth-
esis, secreting reductants, taking citrate as a carrier, utilizing a
hemoglobin–haptoglobin complex and synthesizing hemoly-
sins10. Siderophores represent one of the most well-studied
pathogen virulence factors for the acquisition of iron.
In addition to involving a bacterial response to oxidative
stress11,12 and the formation of bioﬁlms13, siderophores play a
role in pathogen virulence. For example, the depletion of
siderophores in Pseudomonas aeruginosa mutants is dramaticallyFigure 1 Main Mycobacattenuated in burnt mice14. Siderophore mycobactin is essential
for both virulence and survival of MTB15. Unique siderophores
are the well-documented MTB virulence factors and may
constitute suitable targets for TB pharmacotherapies.2. Structure and biosynthesis of Mycobacterium siderophores
Siderophores are small iron-chelating molecules synthesized
by many organisms for iron acquisition and transfer. Their
intracellular level is dynamic and tightly regulated in response
to ﬂuctuations in the environmental iron concentration16.
Siderophores can be classiﬁed as secreted, membrane-bound
and amphiprotic based on their hydrophilicity. Amphiphilic
siderophores from marine bacteria were the ﬁrst to be
separated and characterized17,18. Siderophores can also be
classiﬁed into three major types based on the structure of their
iron-chelating moieties3: Catecholate siderophores, based on
dihydroxybenzoic acid, hydroxamate siderophores, based on
the –N(OH)–CO– group, and mixed siderophores, which
contain both the former moieties.
Mycobacterium siderophores (Fig. 1) are of hydroxamate
and mixed types. Mycobactin is an intracellular lipophilic
siderophore whereas carboxymycobactin and exochelin are
extracellular siderophores. The main siderophores in M. tuber-
culosis are mycobactin and carboxymycobactin. Carboxymyco-
bactin19 is a large family of siderophores bearing a short alkyl
side chain of variable length and unsaturation. They incorpo-
rate a terminal methyl ester motif, which enhances polarity and
solubility and is essential for iron chelation. Both mycobactins20
and carboxymycobactins are salicylate derivatives with one
modiﬁed Ser/Thr and two Lys molecules added19. Most
Mycobacterium siderophores are mycobactin derivatives.
Nonpathogenic Mycobacterium smegmatis has three side-
rophores: a cell envelope-related mycobactin21, a secretedterium siderophores.
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lin is a formylated thymopentin (Fig. 1): -N-(d-N-OCH3,d-
N-OH-R-ornithinyl)-b-alaninyl-d-N-OH-R-ornithinyl-R-allo-
threonin-yl-d-N-OH-S-ornithine. The unconventional peptide
bonds formed between R-amino acids protect the molecule
from peptidase hydrolysis. The rigid chelating center is
hexadentate in an octahedral structure containing three
hydroxamic acid groups.
The extracellular siderophore of Mycobacterium neoaurum
is called exochelin MN. It belongs to a peptide family
containing an unusual b-hydroxyhistidine and an N-methyl
group. This siderophore chelates iron using its two cis-
hydroxamate motifs and the hydroxyl and imidazole nitrogen
of the b-OH-histidine. Mycobacterium leprae also utilizes this
unique exochelin MN to sequester iron25.
Iron is a prerequisite for the growth of mycobacteria
in vitro. Moreover, the growth of mycobacteria mutants
deﬁcient in siderophore synthesis and transport is dramatically
inhibited in an iron-limited environment3,26.
Mycobactins are produced by a polyketide synthase/non-
ribosomal peptide synthetase27. Multiple enzymes are involved
including the core structure synthase salicyloyl-AMP-ligase
MbtA, the polyketide synthases MbtC and MbtD, the
peptide synthases MbtB, MbtE and MbtF, the hydroxylase
MbtG, the isochorismate synthase MbtI and the lipidic
side chain synthases FadD33, FadE14 and Rv1347 (GCN5
N-acetyltransferase)27–33. Exochelin biosynthesis can also be
performed via the nonribosomal peptide synthetase mechan-
ism12,34,35. The six amino acids of the exochelin are added
stepwise mediated by the synthases FxbA, FxbB and FxbC.
Further modiﬁcation is necessary for full activity12,34. The key
enzymes involved in siderophore biosynthesis are putative
targets for novel antibiotics.3. Drug carriers based on mycobacteria siderophores
Siderophores are essential for microbial survival. They can
readily permeate the cell or facilitate the entry of other
compounds. This feature makes them ideal candidates to
transport antibiotics/germicides. Mycobacterium can use xeno-
siderophores produced by other microbes36 and exogenous
siderophores without the ability to exchange ligands can be
utilized as potential drug vectors to overcome the mycobac-
teria permeability barrier. Exogenous siderophores and side-
rophore analogs with bacteriostatic/antibacterial effects are
currently under intensive investigation36,37.
Desferri-exochelin (D-Exo) is hitherto the most well-studied
siderophore drug vehicle. It can arrest the growth of human
vascular smooth muscle cells in vitro making it a potentially
useful treatment for postangioplasty restenosis38. D-Exo can
kill breast cancer cells through an apoptotic effect without
damaging normal human mammary epidermal cells39,40. It
regulates the hypoxic response of breast tumor cells via
inducing hypoxia-inducible factors (HIF) 1a and 2a. The
proliferation of endothelial cells can also be suppressed by
NIP3-induced apoptosis via the synergy of D-Exo with other
HIF-independent pathways41. D-Exo can also remove surplus
iron from organs such as the heart and liver without apparent
toxicity. This unusual feature allows D-Exo to prevent organ
damage stemming from iron-overload in patients withthalassemia42. D-Exo is much more efﬁcient and less cytotoxic
than the currently used iron chelator, deferoxamine.
Mono-, bis- and tris-catecholates and mixed mono- and bis-
catecholate hydroxamates have been synthesized and their
siderophore-like growth promoting effects on mycobacteria
assessed. Some tris-catecholates and bis-catecholate hydroxa-
mates were active in Mycobacterium smegmatis lacking myco-
bactin and exochelin biosynthesis or exochelin permease.
Some compounds conjugated with ampicillin were active
against Gram negative bacteria43 opening a new avenue to
exploit synthetic siderophores or their analogs as drug
carriers.
4. Drug design based on Mycobacterium siderophores
The indispensable role of siderophores in pathogen virulence
and proliferation makes them promising targets for novel
antibiotics. Synthetic mycobactin analogs and heterologous
mycobactins can be utilized by mycobacteria and can promote
the growth of Mycobacterium aurum. Novel drug vectors can
be formulated based on this feature to overcome the imper-
vious cell wall barrier characteristic of mycobacteria44; syn-
thetic N5-OH-N5-acetyl-L-ornithine tripeptide derivatives can
promote the growth of many mycobacteria and Gram negative
bacteria45; some catecholate and/or hydroxamate analogs can
promote the growth of M. smegmatis mutants incapable of
producing mycobactin or exochelin43. Table 1 summarizes
many of the advances in this ﬁeld.
In summary, the logic behind siderophore-based novel
antibiotic discovery is as follows. First, mycobactin analogs
can signiﬁcantly inhibit the growth of bacteria. Second,
compounds directly inhibit the enzymes involved in side-
rophore biosynthesis. Third, compounds modulate iron-
dependent regulator protein (IdeR), i.e. the negative regulator
of siderophore synthetic genes and virulence factors58. Since
further inhibition of IdeR under iron-limiting conditions can
attenuate the virulence of MTB58, this last strategy remains
almost completely unexploited and merits further exploration.
Other strategies being intensively pursued include targeting
shikomic acid 5-dehydrogenase involved in the synthesis of the
mycobactin precursor chorismic acid59 and Irep28 (cell wall-
associated iron-regulated protein)60. Plant-derived compounds
that can dissolve inorganic iron are active against MTB61.
Newly discovered applications of siderophores also deserve
investigation such as the reported immunomodulating activity
of deferrioxamine62.
5. Prospects
Great progress has been made in treating MDR-TB and XDB-
TB. However, the emergence of drug resistant strains seems to
outpace the development of novel antibiotics. A case in point
is capreomycin63. As more leads based on natural products
and new chemical entities based on efﬂux pumps64 and the
siderophore biosynthesis gene cluster enter the drug develop-
ment pipeline, it can only be hoped that TB control will
improve in the near future.
Despite great progress in developing novel siderophore-
based antibiotics, much research remains to be done. This
includes pharmacodynamic and pharmacokinetic studies of
the above-named compounds and assessing the feasibility of
Table 1 Drug or drug leads based on siderophores.
No. Substrate Drug design Strategy Effect References
1 Mycobactin
S/T
Substitute a
catechol–glycine
motif for the
phenol-oxazoline
of the natural
mycobactins S/T
Bind iron and
promote the growth
of many microbes
(especially the
mycobacteria)
46
2 Siderophore Siderophore
analogs
Show antimicrobial
activity against
MTB and Yersinia
pestis; much less
cytotoxic than
cycloheximide and
rifampicin
47
3 Sal-AMS Substitute the
4-position of the
triazole group
Possess/inhibit the
AAAEs in
mycobacterial
siderophore
biosynthesis
48
4 Sal-AMS Structure–
siderophore activity
relationship of the
purine nucleobase
domain of Sal-AMS
Superior
antitubercular
activity
49
5 Nucleoside
antibiotics 1
and 2
Substitute a
b-ketosulfonamide
linkage for the
unstable
acylsulfamate
linkage
Antitubercular
activity; inhibit
MbtA activity and
interrupt MTB
mycobactin
biosynthesis.51–53
50
6 Sal-AMS Substitution New AAAE
inhibitors
49, 54
7 3-OH-4-
Pyridinone
chelating
units
Synthesize tripodal
compounds of the
3-OH-4-pyridinone
family
Strongly inhibit
intramacrophagic
growth of M. avium
by competing for
iron with natural
siderophores
55, 56
8 Siderophore
containing
the sugar
backbone
a–f series (details in the reference) Modify the 2,3,4 or
2,3,6 positions on
the siderophore
sugar backbones
with hydroxamic or
retro-hydroxamic
acid
Promote the growth
of M. smegmatis in
iron-deﬁcient
milieus
57
9 Salicyl-AMP Replace the ‘‘P’’ of
salicyl-AMP with
‘‘S’’
Antibiotic activity
to MTB, Y. pestis
and Y.
pseudotuberculosis in
iron-deﬁcient
milieus
1, 51
10 Isochorismate Mimic the MbtI-
bound intermediate,
isochorismate,
based on a 2,3-
dihydroxybenzoate
scaffold
Inhibit the activity
of MbtI involved in
the ﬁrst step of
siderophore
biosynthesis
15
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and MbtG25,29–33) of siderophore biosynthesis. The discovery
that M. leprae can use exochelin MN originating from
M. neoaurum provides an important impetus to pursue drug
design against this obligate intracellular pathogen25. Models
predicting structure–activity relationships of potential inhibi-
tors derived from siderophore nucleoside reconstitution are of
great potential value65. Furthermore, there may be other
approaches to the discovery of antituberculosis compounds
such as exploiting the siderophore antagonist, siderocalin9.
Broader application of analgesics, antipyretics, anticoagulants
and anti-inﬂammatory drugs based on siderophores is also
important66.
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